{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:35:29Z","timestamp":1792100129888,"version":"4.4.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.prp.2024.155161","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T12:04:56Z","timestamp":1705925096000},"page":"155161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia"],"prefix":"10.1016","volume":"254","author":[{"given":"Mohamed","family":"El-Tanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdi","family":"Nsairat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail I.","family":"Matalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin Fai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A.","family":"Aljabali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachana","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altijana","family":"Hromi\u0107-Jahjefendi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza M.","family":"Tambuwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155161_bib1","doi-asserted-by":"crossref","unstructured":"Peiris, M.N., F. Li, and D.J. Donoghue, BCR: a promiscuous fusion partner in hematopoietic disorders, 2019. 10(28).","DOI":"10.18632\/oncotarget.26837"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-512","article-title":"Regulation of hTERT by BCR-ABL at multiple levels in K562 cells","volume":"11","author":"Chai","year":"2011","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.prp.2024.155161_bib3","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1172\/JCI31771","article-title":"Discovery of the Philadelphia chromosome: a personal perspective","volume":"117","author":"Nowell","year":"2007","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.prp.2024.155161_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","article-title":"Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review","volume":"12","author":"Sampaio","year":"2021","journal-title":"World J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.prp.2024.155161_bib6","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3892\/or.2013.2677","article-title":"Oncogenic chromosomal translocations and human cancer (Review)","volume":"30","author":"Zheng","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2024.155161_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8935-7-1","article-title":"Telomere shortening and telomere position effect in mild ring 17 syndrome","volume":"7","author":"Surace","year":"2014","journal-title":"Epigenetics Chromatin"},{"issue":"5","key":"10.1016\/j.prp.2024.155161_bib9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.hoc.2009.07.007","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"23","author":"Ravandi","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"139","key":"10.1016\/j.prp.2024.155161_bib11","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: evolution of function, regulation, and specificity","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci. Signal"},{"issue":"17","key":"10.1016\/j.prp.2024.155161_bib12","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2015-11-681171","article-title":"Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases","volume":"127","author":"Dasgupta","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.prp.2024.155161_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123327","article-title":"Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.prp.2024.155161_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/01.RES.0000214545.99387.e3","article-title":"Vesicular Trafficking of Tyrosine Kinase Receptors and Associated Proteins in the Regulation of Signaling and Vascular Function","volume":"98","author":"Mukherjee","year":"2006","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.prp.2024.155161_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/cells3020304","article-title":"Mechanisms of activation of receptor tyrosine kinases: monomers or dimers","volume":"3","author":"Maruyama","year":"2014","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.32607\/20758251-2009-1-3-29-51","article-title":"Chemical and functional aspects of posttranslational modification of proteins","volume":"1","author":"Knorre","year":"2009","journal-title":"Acta Nat."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2007-10-118232","article-title":"The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse","volume":"112","author":"Huang","year":"2008","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.prp.2024.155161_bib18","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","article-title":"Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors","volume":"24","author":"Kuribara","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.prp.2024.155161_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020453","article-title":"Murine Models of Acute Myeloid Leukemia.","volume":"20","author":"Almosailleakh","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.prp.2024.155161_bib20","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1073\/pnas.95.13.7457","article-title":"Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase","volume":"95","author":"Taagepera","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.prp.2024.155161_bib21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.embor.7400700","article-title":"c-Abl acetylation by histone acetyltransferases regulates its nuclear-cytoplasmic localization","volume":"7","author":"di Bari","year":"2006","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.cdd.4400626","article-title":"c-Abl: activation and nuclear targets","volume":"7","author":"Shaul","year":"2000","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.cr.7290261","article-title":"Role of c-Abl in the DNA damage stress response","volume":"15","author":"Shaul","year":"2005","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010238","article-title":"Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective","volume":"12","author":"Ong","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.prp.2024.155161_bib25","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.bbamcr.2014.08.003","article-title":"Macromolecular transport between the nucleus and the cytoplasm: Advances in mechanism and emerging links to disease","volume":"1843","author":"Tran","year":"2014","journal-title":"Biochim Biophys. Acta"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI119520","article-title":"BCR\/ABL induces multiple abnormalities of cytoskeletal function","volume":"100","author":"Salgia","year":"1997","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molcel.2015.11.006","article-title":"Targeting Mitosis in Cancer: Emerging Strategies","volume":"60","author":"Dominguez-Brauer","year":"2015","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1110\/ps.051782206","article-title":"An examination of dynamics crosstalk between SH2 and SH3 domains by hydrogen\/deuterium exchange and mass spectrometry","volume":"15","author":"Hochrein","year":"2006","journal-title":"Protein Sci."},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1742-4658.2010.07985.x","article-title":"Roles of the SH2 and SH3 domains in the regulation of neuronal Src kinase functions","volume":"278","author":"Groveman","year":"2011","journal-title":"Febs J."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0092-8674(01)00301-4","article-title":"Dynamic Coupling between the SH2 and SH3 Domains of c-Src and Hck Underlies Their Inactivation by C-Terminal Tyrosine Phosphorylation","volume":"105","author":"Young","year":"2001","journal-title":"Cell"},{"issue":"36","key":"10.1016\/j.prp.2024.155161_bib32","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1303966110","article-title":"Two-state dynamics of the SH3-SH2 tandem of Abl kinase and the allosteric role of the N-cap","volume":"110","author":"Corbi-Verge","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.prp.2024.155161_bib33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J. Exp. Med"},{"issue":"8","key":"10.1016\/j.prp.2024.155161_bib34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.prp.2024.155161_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25184210","article-title":"Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to","volume":"25","author":"Carofiglio","year":"2020","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.prp.2024.155161_bib36","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1074\/jbc.R112.438382","article-title":"Structure and dynamic regulation of Abl kinases","volume":"288","author":"Panjarian","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.prp.2024.155161_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.prp.2024.155161_bib38","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/sj.onc.1201708","article-title":"The kinase activity of c-Abl but not v-Abl is potentiated by direct interaction with RFXI, a protein that binds the enhancers of several viruses and cell-cycle regulated genes","volume":"16","author":"Agami","year":"1998","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.prp.2024.155161_bib39","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.prp.2024.155161_bib40","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12288-013-0316-6","article-title":"Location of the BCR\/ABL Fusion Genes on Both Chromosomes 9 in Ph Negative Young CML Patients: An Indian Experience","volume":"30","author":"Brahmbhatt","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"19","key":"10.1016\/j.prp.2024.155161_bib42","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib43","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med"},{"issue":"10","key":"10.1016\/j.prp.2024.155161_bib44","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib45","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","article-title":"Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway","volume":"13","author":"Puil","year":"1994","journal-title":"Embo J."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun. Signal."},{"issue":"20","key":"10.1016\/j.prp.2024.155161_bib47","doi-asserted-by":"crossref","first-page":"9564","DOI":"10.18632\/oncotarget.2465","article-title":"Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia","volume":"5","author":"Berger","year":"2014","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.prp.2024.155161_bib48","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","article-title":"The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells","volume":"21","author":"Klejman","year":"2002","journal-title":"Embo J."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-021-01111-4","article-title":"MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies","volume":"14","author":"Ahmadi","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.prp.2024.155161_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020523","article-title":"MYC's Fine Line Between B Cell Development and Malignancy","volume":"9","author":"de Barrios","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib52","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1128\/MCB.20.4.1179-1186.2000","article-title":"The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf","volume":"20","author":"Neshat","year":"2000","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2765","article-title":"Leukaemogenesis: more than mutant genes","volume":"10","author":"Chen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib54","first-page":"656","article-title":"Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR","volume":"52","author":"Handschuh","year":"2018","journal-title":"Int J. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib55","article-title":"Re-evaluating the role of BCR\/ABL in chronic myelogenous leukemia","volume":"1","author":"Ross","year":"2014","journal-title":"Mol. Cell Oncol."},{"key":"10.1016\/j.prp.2024.155161_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-016-0049-y","article-title":"Acute lymphoblastic leukemia with e1a3 BCR\/ABL fusion protein. A report of two cases","volume":"5","author":"L\u00f3pez-Andrade","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.leu.2400590","article-title":"The BCR\/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins","volume":"11","author":"Uemura","year":"1997","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.prp.2024.155161_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23115950","article-title":"Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors","volume":"23","author":"Ikeda","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib59","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s13287-021-02659-1","article-title":"Chronic myeloid leukemia stem cells: targeting therapeutic implications","volume":"12","author":"Mojtahedi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12301","article-title":"Does BCR\/ABL1 positive acute myeloid leukemia exist?","volume":"161","author":"Nacheva","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.prp.2024.155161_bib61","first-page":"6707506","article-title":"Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations","volume":"2019","author":"Mariotti","year":"2019","journal-title":"Case Rep. Hematol."},{"issue":"24","key":"10.1016\/j.prp.2024.155161_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.prp.2024.155161_bib63","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1080\/1042819021000039992","article-title":"Quantitative monitoring of BCR\/ABL transcript during STI-571 therapy","volume":"43","author":"Wu","year":"2002","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.prp.2024.155161_bib64","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/cncr.25527","article-title":"Monitoring molecular response in chronic myeloid leukemia","volume":"117","author":"Cortes","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155161_bib65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1525-1578(10)60454-0","article-title":"Clinical applications of BCR-ABL molecular testing in acute leukemia","volume":"5","author":"Nashed","year":"2003","journal-title":"J. Mol. Diagn."},{"issue":"9","key":"10.1016\/j.prp.2024.155161_bib66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/gm191","article-title":"Detection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPET","volume":"2","author":"Shibata","year":"2010","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib67","first-page":"65","article-title":"BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran","volume":"9","author":"Ayatollahi","year":"2018","journal-title":"Casp. J. Intern Med"},{"issue":"7","key":"10.1016\/j.prp.2024.155161_bib68","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.V83.7.1922.1922","article-title":"Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization","volume":"83","author":"Bentz","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12291-018-0779-1","article-title":"A Prognostic and Predictive Study of BCR-ABL Expression Based on Characterization of Fusion Transcripts","volume":"35","author":"Upadhyay","year":"2020","journal-title":"Indian J. Clin. Biochem"},{"issue":"5","key":"10.1016\/j.prp.2024.155161_bib70","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","article-title":"Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"113","author":"Lee","year":"2021","journal-title":"Int J. Hematol."},{"issue":"17","key":"10.1016\/j.prp.2024.155161_bib71","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.3889\/oamjms.2019.752","article-title":"Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia","volume":"7","author":"Jovanovska","year":"2019","journal-title":"Open Access Maced. J. Med Sci."},{"key":"10.1016\/j.prp.2024.155161_bib72","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.2147\/CMAR.S232752","article-title":"Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances","volume":"12","author":"Cumbo","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib73","doi-asserted-by":"crossref","DOI":"10.1186\/s12875-019-1019-3","article-title":"Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study","volume":"20","author":"Fernandez-Lazaro","year":"2019","journal-title":"BMC Fam. Pract."},{"issue":"5","key":"10.1016\/j.prp.2024.155161_bib74","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J."},{"issue":"7","key":"10.1016\/j.prp.2024.155161_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072251","article-title":"Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2020","journal-title":"J. Clin. Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00891-x","article-title":"Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events","volume":"13","author":"Abdelmagid","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib78","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2024.155161_bib79","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/asheducation-2018.1.161","article-title":"The argument for using imatinib in CML","volume":"2018","author":"Claudiani","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.prp.2024.155161_bib81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.prp.2024.155161_bib82","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/bloodadvances.2018018655","article-title":"A second-generation TKI should always be used as initial therapy for CML","volume":"2","author":"Cortes","year":"2018","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.prp.2024.155161_bib83","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.prp.2024.155161_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.742802","article-title":"A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs","volume":"12","author":"Amir","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.prp.2024.155161_bib85","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.prp.2024.155161_bib86","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res Pr."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib87","first-page":"163","article-title":"Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark)","volume":"4","author":"Henkes","year":"2008","journal-title":"Ther. Clin. Risk Manag"},{"issue":"14","key":"10.1016\/j.prp.2024.155161_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143303","article-title":"Mesenchymal Stromal Cells (MSCs): An Ally of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells in Disease Maintenance and Progression within the Bone Marrow Hematopoietic Niche","volume":"14","author":"Fallati","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.prp.2024.155161_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113570","article-title":"Hematopoietic and Chronic Myeloid Leukemia Stem Cells: Multi-Stability versus Lineage Restriction","volume":"23","author":"Brown","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.prp.2024.155161_bib90","doi-asserted-by":"crossref","first-page":"11842","DOI":"10.1073\/pnas.2034201100","article-title":"Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?","volume":"100","author":"Passegu\u00e9","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2024.155161_bib91","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.2147\/CMAR.S314343","article-title":"Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients","volume":"13","author":"Wang","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"2","key":"10.1016\/j.prp.2024.155161_bib92","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5045\/br.2020.2019191","article-title":"Chronic phase of chronic myeloid leukemia presenting with myeloid sarcoma in an adolescent","volume":"55","author":"Lee","year":"2020","journal-title":"Blood Res."},{"issue":"6","key":"10.1016\/j.prp.2024.155161_bib93","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"24","key":"10.1016\/j.prp.2024.155161_bib94","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.prp.2024.155161_bib95","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prp.2024.155161_bib96","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omtn.2017.05.003","article-title":"Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia","volume":"7","author":"Vinhas","year":"2017","journal-title":"Mol. Ther. - Nucleic Acids"},{"issue":"9","key":"10.1016\/j.prp.2024.155161_bib97","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1091\/mbc.e05-01-0010","article-title":"Calcium-activated RAF\/MEK\/ERK Signaling Pathway Mediates p53-dependent Apoptosis and Is Abrogated by \u03b1B-Crystallin through Inhibition of RAS Activation","volume":"16","author":"Li","year":"2005","journal-title":"Mol. Biol. Cell"},{"issue":"12","key":"10.1016\/j.prp.2024.155161_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083510","article-title":"Inhibition of PI3K\/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2","volume":"8","author":"Ding","year":"2013","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib99","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-9-22","article-title":"Effects of nilotinib on regulatory T cells: the dose matters","volume":"9","author":"Fei","year":"2010","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2024.155161_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218444","article-title":"Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+\/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment","volume":"14","author":"Trojani","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2024.155161_bib101","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2146\/ajhp130506","article-title":"Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia","volume":"71","author":"Chung","year":"2014","journal-title":"Am. J. Health-Syst. Pharm.: AJHP: Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.prp.2024.155161_bib102","first-page":"20","article-title":"Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia. Clinical cancer research: an official journal of the American Association for","author":"Gandhi","year":"2014","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2024.155161_bib103","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","article-title":"Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase","volume":"7","author":"Vigneri","year":"2001","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40222-z","article-title":"Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells","volume":"14","author":"Rattigan","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2024.155161_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137093","article-title":"Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?","volume":"22","author":"Soverini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.prp.2024.155161_bib106","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib107","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.prp.2024.155161_bib108","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2009.013797","article-title":"Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia","volume":"95","author":"Park","year":"2010","journal-title":"Haematologica"},{"issue":"41","key":"10.1016\/j.prp.2024.155161_bib109","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib110","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.11940","article-title":"Dual PI3K\/mTOR inhibitor NVP\u2011BEZ235 decreases the proliferation of doxorubicin\u2011resistant K562 cells","volume":"23","author":"Li","year":"2021","journal-title":"Mol. Med Rep."},{"issue":"30","key":"10.1016\/j.prp.2024.155161_bib111","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.2174\/092986711797379267","article-title":"A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken","volume":"18","author":"Gnanasambandan","year":"2011","journal-title":"Curr. Med Chem."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084746","article-title":"Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR\/p70S6K\/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera","volume":"9","author":"Nagao","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040620712461047","article-title":"Comprehensive review of JAK inhibitors in myeloproliferative neoplasms","volume":"4","author":"Sonbol","year":"2013","journal-title":"Ther. Adv. Hematol."},{"issue":"20","key":"10.1016\/j.prp.2024.155161_bib114","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.prp.2024.155161_bib115","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.prp.2024.155161_bib116","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030666","article-title":"KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders","volume":"14","author":"Vendramini","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib118","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/157489209787002461","article-title":"Recent developments in anti-cancer agents targeting the Ras\/Raf\/ MEK\/ERK pathway","volume":"4","author":"Wong","year":"2009","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"7","key":"10.1016\/j.prp.2024.155161_bib119","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2019.03.015","article-title":"Oral MEK 1\/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study","volume":"19","author":"Ragon","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.prp.2024.155161_bib120","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1038\/s41375-020-0972-0","article-title":"Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition","volume":"34","author":"Tambe","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.prp.2024.155161_bib121","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.prp.2024.155161_bib122","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.prp.2024.155161_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143300","article-title":"Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukemia.","volume":"14","author":"Poudel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.prp.2024.155161_bib124","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.prp.2024.155161_bib125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","article-title":"Acquired Resistance to Drugs Targeting Tyrosine Kinases","volume":"138","author":"Rosenzweig","year":"2018","journal-title":"Adv. Cancer Res"},{"key":"10.1016\/j.prp.2024.155161_bib126","article-title":"In Vitro Antineoplastic and Antiviral Activity and In Vivo Toxicity of Geum urbanum L. Extracts","volume":"27","author":"Zaharieva","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2024.155161_bib127","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.semcancer.2020.02.003","article-title":"Turning liabilities into opportunities: Off-target based drug repurposing in cancer","volume":"68","author":"Palve","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib128","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5-6","key":"10.1016\/j.prp.2024.155161_bib129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","article-title":"The role of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"18","author":"Kujawski","year":"2007","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.24249","article-title":"Chronic myeloid leukemia: First-line drug of choice","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.prp.2024.155161_bib131","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib132","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2024.155161_bib133","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.922971","article-title":"Prolonged Survival of a Patient with Chronic Myeloid Leukemia in Accelerated Phase with Recurrent Isolated Central Nervous System Blast Crisis","volume":"21","author":"Bin Salman","year":"2020","journal-title":"Am. J. Case Rep."},{"issue":"6","key":"10.1016\/j.prp.2024.155161_bib134","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.prp.2024.155161_bib135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155161_bib136","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jad.2004.04.002","article-title":"The phenomenology and treatment of interferon-induced depression","volume":"82","author":"Loftis","year":"2004","journal-title":"J. Affect Disord."},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib137","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11899-018-0449-7","article-title":"Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making","volume":"13","author":"Kennedy","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib138","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/0971-5851.142036","article-title":"Current status of hematopoietic stem cell transplant in chronic myeloid leukemia","volume":"35","author":"Gupta","year":"2014","journal-title":"Indian J. Med Paediatr. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib139","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2021.280203","article-title":"The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis","volume":"108","author":"Mei","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2024.155161_bib140","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of Chronic Myeloid Leukemia in Advanced Phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2024.155161_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215370","article-title":"Case of relentless chronic phase of chronic myeloid leukemia.","volume":"2016","author":"Chan","year":"2016","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib142","first-page":"8","article-title":"Chronic Myeloid Leukemia in The 21st Century","volume":"76","author":"Frazer","year":"2007","journal-title":"Ulst. Med J."},{"issue":"10","key":"10.1016\/j.prp.2024.155161_bib143","first-page":"615","article-title":"Post-transplant outcome in chronic myeloid leukemia","volume":"18","author":"Raza","year":"2008","journal-title":"J. Coll. Physicians Surg. Pak."},{"issue":"1","key":"10.1016\/j.prp.2024.155161_bib144","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1182\/asheducation-2016.1.164","article-title":"Chronic myeloid leukemia: sequencing of TKI therapies","volume":"2016","author":"Cortes","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.prp.2024.155161_bib146","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/159479","article-title":"Predicting alloreactivity in transplantation","volume":"2014","author":"Geneugelijk","year":"2014","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.prp.2024.155161_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065764","article-title":"The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation","volume":"24","author":"Dybko","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.prp.2024.155161_bib148","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2014-10-567784","article-title":"The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century","volume":"125","author":"Barrett","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.prp.2024.155161_bib149","first-page":"264","article-title":"Overview of T-cell depletion in haploidentical stem cell transplantation","volume":"10","author":"Daniele","year":"2012","journal-title":"Blood Transfus."},{"key":"10.1016\/j.prp.2024.155161_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760199","article-title":"Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease","volume":"12","author":"Braun","year":"2021","journal-title":"Front Immunol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:01:32Z","timestamp":1767168092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824000724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":149,"alternative-id":["S0344033824000724"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155161","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155161"}}